Alembic Pharmaceuticals gets USFDA's tentative approval for type 2 diabetes drug
The tentatively approved abbreviated new drug application (ANDA) is therapeutically equivalent to the reference listed drug product Glyxambi tablets, 10 mg/5 mg and 25 mg/5 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Diabetes | Diabetes Type 2 | Endocrinology | New Drug Applications | Pharmaceuticals